5.6.3. ART should be continued in all women who commenced HAART for PMTCT with a CD4 cell count of between 350 and 500 cells/μL during pregnancy who are coinfected with HBV or HCV in accordance with the MS-275 supplier BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012 ( www.bhiva.org/PublishedandApproved.aspx ). Grading: 1B There is evidence that continuing ART in patients coinfected with HBV or HCV reduces co-morbidity progression. For HBV, there is

the additional requirement of viral suppression from antiviral drugs (emtricitabine, lamivudine, tenofovir) and the risk of a flare of hepatitis if discontinued (see Section 6.2 Hepatitis C). 5.6.4 ART can be continued in

all women who commenced HAART for PMTCT with a CD4 cell count of between 350 and 500 cells/μL during pregnancy. Grading: 2C On the basis of the above cohort data the Department of Health and Social Services (2011) [153] and International AIDS Society (2010) guidelines [154] for treating adults have now altered their recommendation and advise treating all adults with a CD4 cell count <500 cells/μL. Moreover, two recent retrospective reviews in women discontinuing ART postpartum found an increased risk of death or opportunistic this website infection among women stopping therapy after delivery. The Tennessee study reviewed patients who discontinued therapy postpartum (mean nadir CD4 cell count 332 cells/μL) in an observational cohort of mothers from 1997 to 2008 [145]. Despite being a small cohort (n = 123), the findings indicated an increased rate of AIDS-defining events and death, and non-AIDS-defining events and death, were more frequent in those discontinuing (n = 54) than in those continuing (n = 69), although this was not statistically significant. This is the only study that has examined the use of HAART on clinical outcomes in women with high CD4 cell counts. However, there were many potential

confounders. In a further retrospective study on mothers discontinuing therapy between 1997 and 2005 GPX6 [147], more opportunistic infections and deaths were found in those who discontinued; however, this was a small, uncontrolled review where 46% had previous ART exposure and 36% a pre-ART CD4 cell count of <350 cells/μL. Lastly, in a large cohort of women who were enrolled in South America and followed up for 6–12 weeks after discontinuation of ART given to prevent MTCT, significant falls in the CD4 cell percentage were seen as would be expected [146]. Other studies have shown no detrimental effects on disease progression in discontinuing treatment postnatally.